Female breast cancer surpassed lung cancer, although lung cancer remained leading cause of cancer deaths in 2020
Bimekizumab Superior to Ustekinumab for Plaque Psoriasis
More patients met targets for improvement in Psoriasis Area and Severity Index, Investigator’s Global Assessment response at week 16
Drug survival of Adalimumab and Infliximab in Hidradenitis Suppurativa Patients: A Daily Practice Cohort Study.
Biologics are often required for treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking.To assess the drug survival of anti-TNF …
Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2).
The phase 3 reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for psoriasis treatment are complete.We present 5-year pooled data from reSURFACE 1 and reSURFACE …
Somatostatin receptors: an alternative treatment target for advanced Merkel cell carcinoma.
Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a high risk of returning and spreading. It affects about 2500 new patients every year in the USA. …
Psoriasis: The Skin I’m In – Development of a behaviour change tool to improve the care and lives of people with psoriasis.
Psoriasis is a long-term skin condition associated with considerable life impairment. Extensive literature regarding the needs of patients with psoriasis is not translated into clinical practice.To explore and communicate the …